Nasus Pharma Ltd (NSRX)

$3.60 +0.20 (5.88%)
Market Cap 39.82M
Revenue (ttm) 0.00
Net Income (ttm) -5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 86,600
Avg Vol 232,638
Day's Range N/A - N/A
Shares Out 11.71M
Stochastic %K 54%
Beta N/A
Analysts Strong Sell
Price Target $18.00

Company Profile

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 972 3 573 6632
Address:
Yigal Alon 65, Tel Aviv-Yafo, Israel
RoyalImperial
RoyalImperial Apr. 25 at 5:22 PM
MITQ ✅ Getting ready for a big breakout next week, keep eyes on it! Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. MITQ super undervalued->The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $TDIC $ATOM.X $NSRX $NCT.X ww/
0 · Reply
RoyalImperial
RoyalImperial Apr. 24 at 9:37 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $SES $PRLD $NSRX $INEO ww..1
0 · Reply
KUMO2026
KUMO2026 Apr. 23 at 1:36 PM
$NSRX very nice swing trade
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 23 at 3:50 AM
$NSRX CEO purchased 2,900 shares at $3.76 for a total of $10,904. Teleman Dan Benjamin now owns 156,991 shares. https://ceo-buys.com
0 · Reply
MicsMugz
MicsMugz Apr. 23 at 1:59 AM
$NSRX Interesting
0 · Reply
ghbond
ghbond Apr. 22 at 4:31 PM
$NSRX Finally on Stocktwits! Strong chart, ride the wave.
0 · Reply
KUMO2026
KUMO2026 Apr. 22 at 2:37 PM
$NSRX entered swing trade here
0 · Reply
PulpFinance
PulpFinance Apr. 22 at 2:36 PM
$NSRX
0 · Reply
Redrum781
Redrum781 Apr. 21 at 11:16 PM
$NSRX
0 · Reply
Latest News on NSRX
Nasus Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 12:30 PM EDT - 9 days ago

Nasus Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

Mar 25, 2026, 9:00 AM EDT - 4 weeks ago

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

Mar 19, 2026, 10:06 AM EDT - 5 weeks ago

BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript

What's Going On With Nasus Pharma Stock On Wednesday

Mar 18, 2026, 11:11 AM EDT - 5 weeks ago

What's Going On With Nasus Pharma Stock On Wednesday

Nasus Pharma Transcript: Study result

Mar 16, 2026, 8:00 AM EDT - 5 weeks ago

Nasus Pharma Transcript: Study result

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

Mar 16, 2026, 7:30 AM EDT - 5 weeks ago

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

Nasus Pharma Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 12:30 PM EDT - 6 weeks ago

Nasus Pharma Transcript: Life Sciences Virtual Investor Forum

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Mar 9, 2026, 8:30 AM EDT - 6 weeks ago

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Mar 9, 2026, 8:00 AM EDT - 6 weeks ago

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Nasus Pharma Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 1:20 PM EST - 2 months ago

Nasus Pharma Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Nasus Pharma to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:00 AM EST - 2 months ago

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

Feb 17, 2026, 8:00 AM EST - 2 months ago

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

Nasus Pharma Announces Closing of $15.0 Million Private Placement

Feb 13, 2026, 8:00 AM EST - 2 months ago

Nasus Pharma Announces Closing of $15.0 Million Private Placement

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

Feb 10, 2026, 11:03 PM EST - 2 months ago

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Jan 20, 2026, 8:00 AM EST - 3 months ago

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nasus Pharma CEO Issues 2025 Letter to Shareholders

Dec 22, 2025, 8:00 AM EST - 4 months ago

Nasus Pharma CEO Issues 2025 Letter to Shareholders

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Nov 20, 2025, 8:15 AM EST - 5 months ago

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Nov 18, 2025, 8:00 AM EST - 5 months ago

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nov 6, 2025, 8:00 AM EST - 6 months ago

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Oct 8, 2025, 8:04 AM EDT - 7 months ago

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

Nasus Pharma Announces Closing of Initial Public Offering

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Nasus Pharma Announces Closing of Initial Public Offering

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Aug 13, 2025, 7:30 AM EDT - 9 months ago

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Jul 9, 2025, 5:40 PM EDT - 10 months ago

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Nasus Pharma IPO Registration Document (F-1)

Jul 9, 2025, 3:59 PM EDT - 10 months ago

Nasus Pharma IPO Registration Document (F-1)

RoyalImperial
RoyalImperial Apr. 25 at 5:22 PM
MITQ ✅ Getting ready for a big breakout next week, keep eyes on it! Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. MITQ super undervalued->The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $TDIC $ATOM.X $NSRX $NCT.X ww/
0 · Reply
RoyalImperial
RoyalImperial Apr. 24 at 9:37 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $SES $PRLD $NSRX $INEO ww..1
0 · Reply
KUMO2026
KUMO2026 Apr. 23 at 1:36 PM
$NSRX very nice swing trade
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 23 at 3:50 AM
$NSRX CEO purchased 2,900 shares at $3.76 for a total of $10,904. Teleman Dan Benjamin now owns 156,991 shares. https://ceo-buys.com
0 · Reply
MicsMugz
MicsMugz Apr. 23 at 1:59 AM
$NSRX Interesting
0 · Reply
ghbond
ghbond Apr. 22 at 4:31 PM
$NSRX Finally on Stocktwits! Strong chart, ride the wave.
0 · Reply
KUMO2026
KUMO2026 Apr. 22 at 2:37 PM
$NSRX entered swing trade here
0 · Reply
PulpFinance
PulpFinance Apr. 22 at 2:36 PM
$NSRX
0 · Reply
Redrum781
Redrum781 Apr. 21 at 11:16 PM
$NSRX
0 · Reply